Onconova reports PhIII flop, putting high-risk MDS program on the chopping block

Beleaguered biotech Onconova ran into another setback Monday morning as a Phase III for its lead program flopped once again.

The trial results for rigosertib, which blocks cellular signaling by targeting RAS effector pathways, in high-risk myelodysplastic syndrome patients did not meet its primary endpoint of improved survival.